A Clinical Evaluation of a Vaginal Bowel Control System for the Treatment of Fecal Incontinence in Women (LIFE)

NCT ID: NCT01655498

Last Updated: 2015-05-27

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

61 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to obtain preliminary efficacy and safety data on the use of the LivSure System (now called the "Eclipse™ System") in women with fecal incontinence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaginal Bowel Control

A vaginal bowel control system intended to manage fecal incontinence.

Group Type EXPERIMENTAL

vaginal bowel control system (LivSure)

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaginal bowel control system (LivSure)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LivSure System Eclipse™ System

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* History of FI for at least 6 months
* Baseline diary requirement for min # of FI episodes in a two-week period
* Ability to manage investigational device insertion and removal
* Successful fitting of study device
* Willing and able to give written informed consent to participate in the study

Exclusion Criteria

* Chronic rectal, anal or pelvic pain
* Any vaginal prolapse that extends beyond the plane of the hymen.
* Previous rectal or pelvic floor surgery within the last 12 months (24 months in the case of cancer)
* Congenital anorectal malformation
* Chronic watery diarrhea unmanageable by drugs or diet as primary cause of FI
* Inflammatory bowel disease
* Presence of a vaginal, anal, rectal or urethral fistula or anastomosis
* Presence of a vaginal, rectal or bladder tumor
* Presence of an open wound or tear in the vagina or anus by exam
* Presence or history of rectovaginal fistula
* Atrophic vaginal tissue as determined by symptoms or visualization
* Current vaginal or urinary infection requiring treatment
* History of recurrent urinary or vaginal infections
* Subject is currently pregnant or planning pregnancy in next 5 months
* Concurrent use of any intra-vaginal device that would interfere with LivSure (now called Eclipse) placement or wearing
* Any significant medical condition (e.g., significant psychiatric or neurological disorders, active alcohol/drug abuse, etc.) or other factor that the investigator believes would interfere with study participation and/or increase subject risk
Minimum Eligible Age

19 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pelvalon, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Holly Richter, PhD, MD

Role: PRINCIPAL_INVESTIGATOR

University of Alabama at Birmingham

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Alabama at Birmingham

Birmingham, Alabama, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Matthews CA, Varma MG, Takase-Sanchez MM, Hale DS, Van Drie D, Muir T, Wells E, Jannelli M, Richter HE. Characteristics Associated With Successful Fitting of a Vaginal Bowel Control System for Fecal Incontinence. Female Pelvic Med Reconstr Surg. 2016 Sep-Oct;22(5):359-63. doi: 10.1097/SPV.0000000000000290.

Reference Type DERIVED
PMID: 27564386 (View on PubMed)

Richter HE, Matthews CA, Muir T, Takase-Sanchez MM, Hale DS, Van Drie D, Varma MG. A vaginal bowel-control system for the treatment of fecal incontinence. Obstet Gynecol. 2015 Mar;125(3):540-547. doi: 10.1097/AOG.0000000000000639.

Reference Type DERIVED
PMID: 25730213 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CA003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

IVES for Treatment of UUI and OAB
NCT02992509 COMPLETED EARLY_PHASE1